

2013, 8(4): e61050.

[10] Kemna E, Pickkers P, Nemeth E, et al. Time course analysis of hepcidin, serum iron, and plasma cytokine

levels in humans injected with LPS [J]. Blood, 2005, 106(5): 1864-1866.

# Impact of *Yigong Powder* ( 异功散 ) on Mice with Iron Metabolism Disorder Mediated by Lipopolysaccharide

ZHENG Qin<sup>1</sup>, GUAN Yu<sup>1</sup>, WANG Zhicheng<sup>2</sup>, WANG Jianying<sup>3</sup>, PU Yiqiong<sup>3</sup>, WANG Guohua<sup>1</sup>, ZHANG Xiaofeng<sup>1</sup>, XIA Jing<sup>1</sup>, CUI Lele<sup>4</sup>, LUO Meihong<sup>4</sup>

( 1. Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200071; 2. Huashan Hospital Fudan University; 3. College of Pharmacy, Shanghai University of Traditional Chinese Medicine; 4. Baoshan Branch of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine )

**ABSTRACT Objective** To explore the impact of *Yigong Powder* on iron metabolism disorder induced by inflammation. **Methods** 40 C57BL/6 mice were randomly divided into control group (  $n = 10$  ), *Yigong Powder* group (  $n = 10$  ), lipopolysaccharide group (  $n = 10$  ) and *Yigong Powder* combined with lipopolysaccharide group (  $n = 10$  ). *Yigong Powder* group and *Yigong Powder* combined with lipopolysaccharide group were given 10.57 g/ (  $\text{kg} \cdot \text{d}$  ) of *Yigong Powder* by gavage. Control group was given 0.2 ml of ultrapure water, all for seven days. On the eighth day, lipopolysaccharide group and *Yigong Powder* combined with lipopolysaccharide group were given 1.5 mg/kg of lipopolysaccharide by intraperitoneal injection to establish iron metabolism disorder models. Six hours later, all mice were sacrificed. Blood routine, serum levels of iron and interleukin 6 ( IL-6 ), and content of iron and IL-6 in liver tissue were detected. **Results** Blood routine changed little in every group (  $P > 0.05$  ). Compared with control group, serum level of iron decreased, serum level of IL-6, as well as content of iron and IL-6 in liver tissue increased in lipopolysaccharide group (  $P < 0.05$  ). Compared with lipopolysaccharide group, iron content in liver tissue, as well as IL-6 in serum and liver tissue decreased in *Yigong Powder* combined with lipopolysaccharide group (  $P < 0.05$  ). **Conclusion** *Yigong Powder* could improve iron metabolism disorder mediated by lipopolysaccharide under acute inflammation. The mechanism may relate to decrease of IL-6 in serum and liver tissue.

**Keywords** *Yigong Powder*; lipopolysaccharide; iron metabolism disorder; acute inflammation

( 收稿日期: 2015-01-10; 修回日期: 2015-03-13 )

编辑: 邓 媛

## 颈复康颗粒、腰痛宁胶囊、蚁参蠲痹胶囊临床研究与应用征文获奖名单

由中医杂志社与承德颈复康药业集团有限公司联合主办的“颈复康颗粒、腰痛宁胶囊、蚁参蠲痹胶囊临床研究与应用征文”，经专家评审，获奖论文如下。

一等奖: 范璐 ( 蚁参蠲痹胶囊对大鼠佐剂性关节炎保护作用及其机制研究 ); 孙世光等 ( 蚁参蠲痹胶囊治疗类风湿性关节炎的系统评价 )。

二等奖: 石彩云等 ( 颈复康颗粒联合甲钴胺片治疗糖尿病远端对称性多发性神经病变 47 例临床观察 ); 臧海洋 ( 颈复康颗粒治疗偏头痛 48 例临床观察 ); 张文义等 ( 腰痛宁胶囊加穴位艾灸治疗腰肌劳损 100 例 ); 周利军等 ( 蚁参蠲痹胶囊治疗类风湿关节炎 108 例临床观察 ); 闵重函等 ( 蚁参蠲痹胶囊治疗类风湿性关节炎的疗效观察 ); 田谧 ( 蚁参蠲痹胶囊治疗痛风伴高脂血症 52 例疗效观察 ); 史耀勋 ( 蚁参蠲痹胶囊治疗痛风性肾病的临床研究 ); 赖建荣等 ( 颈复康颗粒联合前列地尔注射液快速缓解颈性眩晕的疗效观察 )。

三等奖: 赖建荣等 ( 颈复康颗粒联合前列地尔注射液治疗颈性眩晕的疗效观察 ); 张金龙 ( 颈复康颗粒治疗慢性脑供血不足患者临床疗效观察 ); 周利军等 ( 颈复康颗粒治疗椎动脉型颈椎病 128 例临床观察 ); 吴建华 ( 颈复康颗粒治疗椎动脉型颈椎病 50 例疗效观察 ); 杨政华等 ( 腰痛宁胶囊对西藏高原痛风病的治疗与体会 ); 李怀生等 ( 腰痛宁胶囊联合壮骨关节丸治疗腰椎骨质增生 34 例 ); 杨代权 ( 腰痛宁胶囊临床应用举例 ); 刘少林等 ( 腰痛宁胶囊配合牵引治疗腰椎间盘突出症临床观察 ); 周利军等 ( 腰痛宁胶囊治疗类风湿关节炎 98 例临床观察 ); 王木闰 ( 腰椎间盘突出症应用腰痛宁胶囊的治疗经验 ); 罗志军等 ( 中西医结合治疗颈椎病综合症的疗效观察 )。

优秀奖: 黄根 ( 颈椎综合症中西医结合治疗临床体会 ); 何重敏 ( 内服外敷中药配合手法治疗颈椎病 48 例疗效观察 ); 申湘葵等 ( 腰痛宁胶囊在腰椎间盘突出症中的临床应用 ); 王友民 ( 治疗颈椎病良药有奇效 )。

获奖证书及奖金将由主办单位邮寄至第一作者。